Search research articles
Contact Us
Filters
Showing results (1-10 of 48) with videos related to
Page
of 5
Sort By:
Canadian Journal of Diabetes
|
March 14, 2022
Sodium-Glucose Cotransporter-2 Inhibitors Increase Risk of Diabetic Ketoacidosis in Adults With Type 2 Diabetes: Should We Be Concerned in People Without Diabetes?
Ronald M Goldenberg
Canadian Journal of Diabetes
|
May 24, 2014
Management of unmet needs in type 2 diabetes mellitus: the role of incretin agents
Ronald M Goldenberg
Journal of Diabetes and Its Complications
|
August 23, 2022
Progression of retinopathy with glucagon-like peptide-1 receptor agonists with cardiovascular benefits in type 2 diabetes - A systematic review and meta-analysis
Ronald M Goldenberg
Diabetes, Obesity & Metabolism
|
October 29, 2025
An indirect treatment comparison of tirzepatide 10 and 15 mg versus high-dose semaglutide 7.2 mg in people with obesity and type 2 diabetes
Ronald M Goldenberg
Diabetes, Obesity & Metabolism
|
April 5, 2024
A comment on 'Glucagon-like peptide-1 receptor agonists and risk of thyroid cancer: A systematic review and meta-analysis of randomized controlled trials'
Ronald M Goldenberg
Clinical Therapeutics
|
November 28, 2017
Choosing Dipeptidyl Peptidase-4 Inhibitors, Sodium-glucose Cotransporter-2 Inhibitors, or Both, as Add-ons to Metformin: Patient Baseline Characteristics Are Crucial
Ronald M Goldenberg
Diabetes, Obesity & Metabolism
|
November 28, 2023
A comment on tirzepatide versus glucagon-like peptide-1 receptor agonists and heart rate with regard to 'Impact of a dual glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist tirzepatide on heart rate among patients with type 2 diabetes: A systematic review and pairwise and network meta-analysis'
Ronald M Goldenberg
Canadian Journal of Diabetes
|
March 7, 2017
WITHDRAWN: The Role of Sodium-Glucose Cotransporter 2 Inhibitors in the Management of Type 2 Diabetes
Oren Steen, Ronald M Goldenberg
Canadian Journal of Diabetes
|
September 10, 2018
Semaglutide: Review and Place in Therapy for Adults With Type 2 Diabetes
Ronald M Goldenberg, Oren Steen
Canadian Journal of Diabetes
|
December 5, 2024
Pharmacologic Glycemic Management of Type 2 Diabetes in Adults---2024 Update: An Opportunity Lost to Move Beyond First-line Metformin
Jill Trinacty, Ronald M Goldenberg
Page
of 5
Search research articles
Search
Showing results (1-10 of 48) with videos related to
Sort By:
Page
of 5
Canadian Journal of Diabetes
|
March 14, 2022
Sodium-Glucose Cotransporter-2 Inhibitors Increase Risk of Diabetic Ketoacidosis in Adults With Type 2 Diabetes: Should We Be Concerned in People Without Diabetes?
Ronald M Goldenberg
Canadian Journal of Diabetes
|
May 24, 2014
Management of unmet needs in type 2 diabetes mellitus: the role of incretin agents
Ronald M Goldenberg
Journal of Diabetes and Its Complications
|
August 23, 2022
Progression of retinopathy with glucagon-like peptide-1 receptor agonists with cardiovascular benefits in type 2 diabetes - A systematic review and meta-analysis
Ronald M Goldenberg
Diabetes, Obesity & Metabolism
|
October 29, 2025
An indirect treatment comparison of tirzepatide 10 and 15 mg versus high-dose semaglutide 7.2 mg in people with obesity and type 2 diabetes
Ronald M Goldenberg
Diabetes, Obesity & Metabolism
|
April 5, 2024
A comment on 'Glucagon-like peptide-1 receptor agonists and risk of thyroid cancer: A systematic review and meta-analysis of randomized controlled trials'
Ronald M Goldenberg
Clinical Therapeutics
|
November 28, 2017
Choosing Dipeptidyl Peptidase-4 Inhibitors, Sodium-glucose Cotransporter-2 Inhibitors, or Both, as Add-ons to Metformin: Patient Baseline Characteristics Are Crucial
Ronald M Goldenberg
Diabetes, Obesity & Metabolism
|
November 28, 2023
A comment on tirzepatide versus glucagon-like peptide-1 receptor agonists and heart rate with regard to 'Impact of a dual glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist tirzepatide on heart rate among patients with type 2 diabetes: A systematic review and pairwise and network meta-analysis'
Ronald M Goldenberg
Canadian Journal of Diabetes
|
March 7, 2017
WITHDRAWN: The Role of Sodium-Glucose Cotransporter 2 Inhibitors in the Management of Type 2 Diabetes
Oren Steen, Ronald M Goldenberg
Canadian Journal of Diabetes
|
September 10, 2018
Semaglutide: Review and Place in Therapy for Adults With Type 2 Diabetes
Ronald M Goldenberg, Oren Steen
Canadian Journal of Diabetes
|
December 5, 2024
Pharmacologic Glycemic Management of Type 2 Diabetes in Adults---2024 Update: An Opportunity Lost to Move Beyond First-line Metformin
Jill Trinacty, Ronald M Goldenberg
Page
of 5